PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2019

Amygdalin (Vitamin B17) pretreatment attenuates experimentally induced acute autoimmune hepatitis through reduction of CD4+ cell infiltration.

Mouse / Chemical/toxin

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 31100343 ↗2019Reported benefit

Amygdalin (Vitamin B17) pretreatment attenuates experimentally induced acute autoimmune hepatitis through reduction of CD4+ cell infiltration.

MouseChemical/toxinmalen = 30 adult male mice, three groupsintraperitoneal5 mg/kgPretreatment before Concanavalin A challenge

Model: Concanavalin A-induced acute autoimmune hepatitis, single intravenous injection of Concanavalin A 15 mg/kg

Amygdalin pretreatment significantly reversed the rises in ALT, AST and MDA, the falls in SOD and GSH, the histological damage and the increased CD4-positive cell infiltration seen after Concanavalin A.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.